<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[biotech Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/biotech.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to biotech]]></description>
	<s:counts start="0" returned="20" found="894" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Financing Drug Discovery: Recent Deals]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175397-financing-drug-discovery-recent-deals%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[The Burrill Report submits:  by Marie Daghlian A smattering of deals and financings marked the relatively quiet days before Thanksgiving. San Diego-based biotech Receptos closed a two-tranche $25 million series A financing. The company is focused on identifying and developing best- and first-in-class therapeutic candidates that target a family...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 26 Nov 2009 12:41:16 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/the+burrill+report.html"><![CDATA[The Burrill Report]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="tickers">BIIB</category>
	</item>
	<item>
		<title><![CDATA[Bristol-Myers Squibb Sees Perfect Timing to Divest Huge Mead Johnson Nutrition Stake]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175393-bristol-myers-squibb-sees-perfect-timing-to-divest-huge-mead-johnson-nutrition-stake%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[The Burrill Report submits:  Bristol-Myers Squibb BMY will sell its last non-biopharmaceutical holding, a majority stake in Mead Johnson Nutrition MJN, the company said. The pediatric nutrition company produces Enfamil baby formula and is a leading supplier of children&#8217;s nutritional products globally. Bristol-Myers&#8217; move, part of a wider healthcare...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 26 Nov 2009 12:16:58 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/the+burrill+report.html"><![CDATA[The Burrill Report]]></category>
		<category domain="http://resources.bnet.com/topic/bristol-myers+squibb+co..html"><![CDATA[Bristol-Myers Squibb Co.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BMY</category>
		<category domain="tickers">BMY</category>
	</item>
	<item>
		<title><![CDATA[Pfizer Increases R&D Commitment in China]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175392-pfizer-increases-r-d-commitment-in-china%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  Pfizer (NYSE: PFE) will expand its China R&D operations by adding facilities in central and western China, according to a Reuters story. The company will build a new clinical R&D center in Wuhan, which will support global clinical drug programs, including Phase I-IV clinical trials. Pfizer...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 26 Nov 2009 12:09:37 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[FDA Approves Gen-Probe Assay]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175462-fda-approves-gen-probe-assay%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   Recently, Gen-Probe Inc. GPRO announced that it has received the green light from the U.S. Food and Drug Administration FDA to market ProParaflu Plus assay. The assay, developed by Prodesse, a wholly-owned subsidiary of Gen-Probe, is a molecular test for detecting and differentiating parainfluenza 1, 2,...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 26 Nov 2009 11:19:39 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/gen-probe+inc..html"><![CDATA[Gen-Probe Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GPRO</category>
		<category domain="tickers">GPRO</category>
	</item>
	<item>
		<title><![CDATA[Insider Buying Bodes Well For Orexigen]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175428-insider-buying-bodes-well-for-orexigen%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Ruthanne Williams Roussel submits: Domain Partners, Orexigen Therapeutic's founding VC, has upped its stake in Orexigen OREX through a series of recent share purchases on the open market, according to a series of Forms 4 filed with the SEC on November 24.  The purchases total just over 400,000 shares...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 26 Nov 2009 02:21:49 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ruthanne+williams+roussel.html"><![CDATA[Ruthanne Williams Roussel]]></category>
		<category domain="http://resources.bnet.com/topic/orexigen+therapeutics+inc..html"><![CDATA[Orexigen Therapeutics Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">OREX</category>
		<category domain="tickers">OREX</category>
	</item>
	<item>
		<title><![CDATA[CytRx Announces First of Two Positive Developments Ahead]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175426-cytrx-announces-first-of-two-positive-developments-ahead%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Just as readers of BioMedReports were told on Monday, CytRx Corporation (NASDAQ:CYTR) announced the first of two key news developments for the company on Tuesday. See the Reuters Story here. by M. E. Garza]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 26 Nov 2009 02:17:07 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
		<category domain="http://resources.bnet.com/topic/cytrx+corp..html"><![CDATA[CytRx Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CYTR</category>
		<category domain="tickers">CYTR</category>
	</item>
	<item>
		<title><![CDATA[SIGA Shares Could Double on Pending Government News]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175419-siga-shares-could-double-on-pending-government-news%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[BioMedReports has learned that shares of this bio-defense company engaged in the discovery, development and commercialization of products for use in defense against biological warfare agents, such as smallpox and arenaviruses is expecting big news and government orders.Our Subscribers were alerted Monday that a series of big government orders are...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 26 Nov 2009 01:50:37 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
		<category domain="http://resources.bnet.com/topic/siga+technologies+inc..html"><![CDATA[SIGA Technologies Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SIGA</category>
		<category domain="tickers">SIGA</category>
	</item>
	<item>
		<title><![CDATA[Short Covering on Siga's Big News Makes for Happy Holidays]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175197-short-covering-on-siga-s-big-news-makes-for-happy-holidays%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[VFC submits:  Shares of Siga Technologies, Inc. SIGA broke the eight dollar mark Tuesday afternoon on anticipation of the possibility that some big government orders could be imminent. BioMedReports issued a mid-day trade alert on Tuesday, alerting readers that the recent price action of the SIGA stock could indicate...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 25 Nov 2009 12:19:36 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/vfc%2527s+stock+house.html"><![CDATA[VFC's Stock House]]></category>
		<category domain="http://resources.bnet.com/topic/siga+technologies+inc..html"><![CDATA[SIGA Technologies Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SIGA</category>
		<category domain="tickers">SIGA</category>
	</item>
	<item>
		<title><![CDATA[Holiday Cheer: Cel-Sci Should Have Good News]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175277-holiday-cheer-cel-sci-should-have-good-news%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[VFC submits:  Shares of Cel Sci Corp. CVM continued to hover right around the $1.30 mark even after TheStreet.com's infamous biotech blogger thrust his most recent blogging salvo at Cel Sci in an attempt to keep his ongoing vendetta against the company alive - for reasons that are still...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 25 Nov 2009 05:06:10 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/vfc%2527s+stock+house.html"><![CDATA[VFC's Stock House]]></category>
		<category domain="http://resources.bnet.com/topic/cel-sci+corp..html"><![CDATA[CEL-SCI Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CVM</category>
		<category domain="tickers">CVM</category>
	</item>
	<item>
		<title><![CDATA[Genzyme's Renagel / Renvela Franchise: Investors Would Be Wise to Reevaluate]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175269-genzyme-s-renagel-renvela-franchise-investors-would-be-wise-to-reevaluate%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[This is a follow up to my previous post regarding the news that development of Genzyme&#8217;s GENZ follow-on product to its Renagel/Renvela franchise is being discontinued. The product, named GENZ-644470, is an advanced phosphate binder APB that was hoped to have demonstrated a superior clinical profile compared to predecessor Renvela....]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 25 Nov 2009 04:31:44 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/mark+mitchell.html"><![CDATA[Mark Mitchell]]></category>
		<category domain="http://resources.bnet.com/topic/genzyme+corp..html"><![CDATA[Genzyme Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/isis+pharmaceuticals+inc..html"><![CDATA[Isis Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GENZ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ISIS</category>
		<category domain="tickers">GENZ,ISIS</category>
	</item>
	<item>
		<title><![CDATA[Azimuth Opportunity Bets on Poniard's Survival]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175205-azimuth-opportunity-bets-on-poniard-s-survival%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[I was poring over Poniard Pharmaceuticals'  PARD past press releases and financial reports this weekend, wondering how close this Biotech really was to shutting its doors forever. Things certainly did not look rosy. Last Monday, November 16 the company announced that the pivotal Phase 3 trial of its lead...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 25 Nov 2009 01:05:20 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/ivan+mutaftchiev.html"><![CDATA[Ivan Mutaftchiev]]></category>
		<category domain="http://resources.bnet.com/topic/poniard+pharmaceuticals+inc..html"><![CDATA[Poniard Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PARD</category>
		<category domain="tickers">PARD</category>
	</item>
	<item>
		<title><![CDATA[China Sky's Financial Statements: Huge Discrepancies]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175055-china-sky-s-financial-statements-huge-discrepancies%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[On August 6th, we first reported on discrepancies between the financial statements of China Sky One Medical, Inc. CSKI filed with U.S. and Chinese regulatory agencies.  CSKI files consolidated financial statements with the U.S. Securities and Exchange Commission SEC, and CSKI's operating subsidiaries, all located in China, file financial...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 24 Nov 2009 06:58:12 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/manuel+asensio.html"><![CDATA[Manuel Asensio]]></category>
		<category domain="http://resources.bnet.com/topic/china+sky+one+medical+inc..html"><![CDATA[China Sky One Medical Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CSKI</category>
		<category domain="tickers">CSKI</category>
	</item>
	<item>
		<title><![CDATA[China Sky's Financial Irregularities Continue in Third Quarter Earnings]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175047-china-sky-s-financial-irregularities-continue-in-third-quarter-earnings%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[China Sky One Medical, Inc. CSKI released its third-quarter earnings on November 17, 2009.  The financial irregularities that asensio.com began reporting on in April 2009 continued to be evident in CSKI&#8217;s third-quarter financial statements. China Sky continues to report a questionably low inventory level.  asensio.com compared CSKI to...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 24 Nov 2009 06:54:06 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/manuel+asensio.html"><![CDATA[Manuel Asensio]]></category>
		<category domain="http://resources.bnet.com/topic/china+sky+one+medical+inc..html"><![CDATA[China Sky One Medical Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CSKI</category>
		<category domain="tickers">CSKI</category>
	</item>
	<item>
		<title><![CDATA[CytRx Corporation: Key Developments Ahead]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175035-cytrx-corporation-key-developments-ahead%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[The clouds of darkness that have been hanging over CytRx Corporation (NASDAQ:CYTR), may soon be cast aside. The stock, which has traded as low as $.24 earlier this year, appears to be on the rebound with at least two key developments on the horizon.On Friday morning, after seeing the stock...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 24 Nov 2009 05:25:15 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
		<category domain="http://resources.bnet.com/topic/cytrx+corp..html"><![CDATA[CytRx Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CYTR</category>
		<category domain="tickers">CYTR</category>
	</item>
	<item>
		<title><![CDATA[Techne Corporation: Good Risk/Reward Proposition]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F174740-techne-corporation-good-risk-reward-proposition%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Techne Corporation TECH is a mid-cap biotechnology company that offers a good risk/reward profile, It is engaged in the development and manufacture of biotechnology products and hematology calibrators and controls. The company appears to be richly priced as compared to its competitors. However, we think this is a hidden gem....]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 23 Nov 2009 12:09:01 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ron+sommer.html"><![CDATA[Ron Sommer]]></category>
		<category domain="http://resources.bnet.com/topic/techne+corp..html"><![CDATA[Techne Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">TECH</category>
		<category domain="tickers">TECH</category>
	</item>
	<item>
		<title><![CDATA[China Nuokang Bio-Pharmaceutical Banks on a Favorable U.S. IPO]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F174956-china-nuokang-bio-pharmaceutical-banks-on-a-favorable-u-s-ipo%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  China Nuokang Bio-Pharmaceutical NKBP, a company focused on hematological and cardiovascular drugs, will offer 4.5 million ADSs on the Nasdaq exchange at a price between $10 and $12. The mid-point of the range represents a $50 million debut for Nuokang. The offering gives further evidence that...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 23 Nov 2009 11:13:07 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
	</item>
	<item>
		<title><![CDATA[CytRx: Technical Breakout Imminent]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F174834-cytrx-technical-breakout-imminent%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/23/09 on CytRx Corporation CYTR. Shares of the company finished trading during 11/20/09 at $1.35 per share, up 20.18% from the opening bell on heavy buying pressure. As of 11/18/09, the biopharmaceutical company announced plans to initiate an...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 23 Nov 2009 07:19:38 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/michael+catalin+vlaicu.html"><![CDATA[Michael Catalin Vlaicu]]></category>
		<category domain="http://resources.bnet.com/topic/cytrx+corp..html"><![CDATA[CytRx Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CYTR</category>
		<category domain="tickers">CYTR</category>
	</item>
	<item>
		<title><![CDATA[Expiration Trade Behind Osiris Activity]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F174610-expiration-trade-behind-osiris-activity%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[optionMONSTER submits:  By Chris McKhann As we close in on expiration at the end of today's session, traders are rolling out positions that they don't want to be without going into Monday. That's what we are seeing today in Osiris Therapeutics OSIR, where traders are rolling put positions out...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 20 Nov 2009 11:26:50 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/optionmonster.html"><![CDATA[optionMONSTER]]></category>
		<category domain="http://resources.bnet.com/topic/osiris+therapeutics+inc..html"><![CDATA[Osiris Therapeutics Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">OSIR</category>
		<category domain="tickers">OSIR</category>
	</item>
	<item>
		<title><![CDATA[A Possible New Indication for Progenix's Relistor Could Revive Its Fortunes]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F174487-a-possible-new-indication-for-progenix-s-relistor-could-revive-its-fortunes%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[David Greene submits: On Wednesday (Nov. 18), Progenic's Pharmaceutical PGNX, received some good news in the form of a Reuters story stating that the widely-used painkiller drug, morphine, may actually accelerate cancer growth in patients. Researchers in the US have results from two studies that show that morphine could be...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 20 Nov 2009 03:07:33 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/david+greene.html"><![CDATA[David Greene]]></category>
		<category domain="http://resources.bnet.com/topic/progenics+pharmaceuticals+inc..html"><![CDATA[Progenics Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PGNX</category>
		<category domain="tickers">PGNX</category>
	</item>
	<item>
		<title><![CDATA[Santarus' Zegrid Facing Back-to-Back FDA Approval Dates]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F174464-santarus-zegrid-facing-back-to-back-fda-approval-dates%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[R. Saito submits: Santarus&#8217; SNTS main drug, Zegerid, is coming up on back-to-back FDA approval dates in early December.  Zegerid is a proprietary immediate-release formulation that combines the proton pump inhibitor omeprazole with the antacid sodium bicarbonate indicated for  upper gastrointestinal diseases and disorders, including gastrointestinal reflux disease...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 20 Nov 2009 01:05:39 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/r.+saito.html"><![CDATA[R. Saito]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
</channel>
</rss>
